Physician profile
Thomas Kerrigan
NPI 1073134904
$21,845.49
in general payments reported to CMS, 2019-2025
15 companies · $21K in 2025
The $21K reported for 2025 was more than what 93% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $970 · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $20K · Food and Beverage: $1,845.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $20,000.00 |
| Food and Beverage | $1,845.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $20,000.00 | 2025 | |
| Abbvie INC. | $972.47 | 2024-2025 | |
| Lundbeck LLC | $149.36 | 2024 | Vyepti, Rexulti |
| Ucb, INC. | $146.99 | 2024-2025 | Rystiggo, Briviact |
| Teva Pharmaceuticals USA, INC. | $110.22 | 2024-2025 | Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $94.88 | 2024-2025 | Ingrezza |
| Eisai INC. | $71.63 | 2025 | |
| Amneal Pharmaceuticals LLC | $65.96 | 2025 | Crexont |
| Merz Pharmaceuticals, LLC | $65.36 | 2024-2025 | Xeomin, Ampyra, Inbrija |
| Genentech USA, INC. | $52.19 | 2024-2025 | Ocrevus, Ocrevus Zunovo |
| Abbott Laboratories | $39.65 | 2025 | Infinity |
| Kyowa Kirin, INC. | $21.99 | 2024 | Nourianz |
| Otsuka America Pharmaceutical, INC. | $20.46 | 2025 | Rexulti |
| Sk Life Science, INC. | $18.24 | 2024 | |
| Jazz Pharmaceuticals INC. | $16.09 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Kerrigan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.